|Bid||173.35 x 800|
|Ask||194.04 x 800|
|Day's Range||176.30 - 178.62|
|52 Week Range||123.00 - 178.62|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||52.60|
|Earnings Date||Apr 22, 2019 - Apr 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||176.76|
NEW ORLEANS , Feb. 15, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 02/12/2019 at an average price of $176.9 a share.
NEW YORK, Feb. 12, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of CAS Medical Systems, Inc. (NASDAQ: CASM) on.
Edwards Lifesciences stock topped a buy point Tuesday on its $100 million plan to buy Cas Medical Systems. IBD 50 stock PRA Health Sciences also broached an entry point.
NEW YORK , Feb. 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against CAS Medical Systems, Inc. (NASDAQ: CASM) and its board of directors for breach of fiduciary duty concerning ...
CAS Medical is a medical tech company that focuses on non-invasive monitoring of tissue oxygenation in the brain. Edwards will buy CAS Medical in an all-cash transaction for $2.45 per share, or an equity value of about $100 million, according to the terms of the deal.
NEW YORK, Feb. 12, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CAS Medical Systems, Inc. (“CASMED”.
Shares of CAS Medical Systems Inc. rocketed 54% toward a six-month high in morning trade Tuesday, enough to pace all Nasdaq gainers, after the medical technology company agreed to be acquired by Edwards Lifesciences Corp. in a cash deal valued at $100 million. Under terms of the deal, Edwards will pay $2.45 for each CAS share outstanding, which is 56% above Monday's closing price of $1.57. The deal price implies a $70.7 million market capitalization for CAS. Edwards' stock tacked on 0.7%. "Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making, said Katie Szyman, vice president of critical care at Edwards. "We believe the incorporation of CASMED's FORE-SIGHT technology into Edwards' leading hemodynamic monitoring platform, along with Edwards' predictive analytics capability, will strengthen Edwards' leadership in smart monitoring technologies by providing physicians with a more comprehensive status of their surgical and critically ill patients." CAS shares have not run up 28% over the past three months and Edwards' stock has rallied 18%, while the S&P 500 has gained 0.1%.
IRVINE, Calif. and BRANFORD, Conn., Feb. 12, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has entered into a definitive merger agreement to acquire CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain. "Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making," said Katie Szyman, Edwards' corporate vice president, critical care.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! This article is written for those whoRead More...
Edwards Lifesciences Corp NYSE:EWView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $12.42 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Br, Feb. 06, 2019 -- In new independent research reports released early this.
Medical device stocks remain supported by favorable conditions that should see sales grow. Watch these three stocks for a 52-week breakout.
The Dow Jones industrials rallied 100 points early Friday after a strong jobs report. Amazon stock's Q4 earnings weighed on the Nasdaq composite.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 31) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0.00% and 0.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Edwards earnings of $1.17 per share, on an adjusted basis, met analyst expectations for the fourth quarter. Sales of $978 million and $983 million in adjusted sales beat analyst views.
The Irvine, California-based company said it had net income of 3 cents per share. Earnings, adjusted for non-recurring costs, were $1.17 per share. The results met Wall Street expectations. The average ...
U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below ...